On this Page
- What is an Open-Label Study?
- When are Open-Label Studies used in Clinical Trials?
- How does Clinion support Open-Label Studies?
- What it looks like in practice
- Related Terms
- Related Articles
- Category
- What is an Open-Label Study?
- When are Open-Label Studies used in Clinical Trials?
- How does Clinion support Open-Label Studies?
- What it looks like in practice
- Related Terms
- Related Articles
- Category
What is an Open-Label Study?
An open-label study is a type of clinical trial in which both the participants and the study team know which treatment each participant is receiving. Unlike blinded studies, treatment assignments are not concealed, allowing all involved parties to know the investigational product being administered.
Open-label studies may be conducted as standalone trials or as extension studies following blinded clinical trials.
When are Open-Label Studies used in Clinical Trials?
Open-label studies are commonly used when blinding is not practical or necessary. They may be conducted in early-phase clinical trials, long-term extension studies, or studies where treatment administration or monitoring requires knowledge of the assigned intervention.
Although treatment allocation is not concealed, study procedures, participant monitoring, and data collection continue according to the approved protocol.
How does Clinion support Open-Label Studies?
During study setup, study teams can configure open-label study designs, treatment arms, participant allocation rules, visit schedules, and drug dispensing workflows within Clinion's unified eClinical platform. Because treatment assignments are visible, the platform supports transparent participant management while maintaining protocol-defined workflows, study oversight, and complete traceability across connected systems.
Clinion RTSM also supports treatment allocation, investigational product dispensing, and drug supply management for open-label studies, helping ensure that participants receive the correct treatment throughout the trial.
What it looks like in practice
A participant completes a one-year blinded clinical trial evaluating a new treatment for rheumatoid arthritis. After the blinded phase ends, eligible participants are invited to join an open-label extension study where everyone receives the investigational treatment. Both the participant and the study team know which treatment is being administered while long-term safety and effectiveness continue to be monitored.
Related Terms
Related Articles
Category
Study Setup & Design